Status:
ACTIVE_NOT_RECRUITING
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Lead Sponsor:
Kresten Krarup Keller
Collaborating Sponsors:
Aarhus University Hospital
Conditions:
Polymyalgia Rheumatica
Giant Cell Arteritis
Eligibility:
All Genders
50+ years
Brief Summary
Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects. P...
Eligibility Criteria
Inclusion
- Patients suspected of PMR.
- Age above 50
- Pain of the proximal muscles.
Exclusion
- Peroral, intraarticular, intramuscular and dermal application of glucocorticoids within the last 3 month.
- Previous prednisolone treatment for GCA/PMR
- Unable to give consent.
- Symptoms of GCA (headache, jaw claudication, vision disturbances).
- Active malignant cancers within the last 5 years (except basal cell carcinoma).
- Other inflammatory rheumatic diseases (eg. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritits, gout).
- Uncontrolled diseases (eg severe active astma, cardiac disease with NYHA class IV)
- Treatment with peroral oestrogens, aminogluthethimid, trilostan, ketoconazole, fluconazol, etomidate, phenobarbital, phenytoin, rifampicin, metyrapon, mitotane.
- Known primary or secondary adrenal insufficiency.
Key Trial Info
Start Date :
September 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2027
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT04519580
Start Date
September 14 2020
End Date
June 30 2027
Last Update
September 24 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Rheumatology, Aarhus University Hospital
Aarhus, Denmark, 8200
2
Department of Rheumatology, Horsens Regional Hospital
Horsens, Denmark, 8700
3
Diagnostic Centre, Silkeborg Regional Hospital
Silkeborg, Denmark, 8600